Division of Medical Oncology Announces Leadership Changes
Matthew Ellis, MB, BChir, PhD
Ramaswamy Govindan, MD
Greg Longmore, MD
Lee Ratner, MD
March 2, 2011 – The Division of Oncology at Washington University School of Medicine in St. Louis has announced a series of leadership changes as a result of programmatic enhancement and expansion. Faculty members in the division, based within the medical school’s Department of Medicine, also are members of the Siteman Cancer Center.
Greg Longmore, MD, has been named co-director of the Section of Molecular Oncology in the Division of Oncology. Longmore has been a faculty member at the School of Medicine for 18 years, most recently serving as professor in the Division of Hematology. He joins Lee Ratner, MD, professor of medicine, who also serves as co-director of the Section of Molecular Oncology, which focuses primarily on research and teaching.
“Dr. Longmore is an accomplished and nationally recognized physician-scientist who studies mechanisms of solid tumor initiation and progression,” says John DiPersio, MD, PhD, director of the Division of Oncology and associate director of the Siteman Cancer Center. “He will both complement our ongoing basic science activities and provide additional mentoring for our junior faculty members and fellows.” Longmore’s appointment was effective Feb. 1.
Also effective Feb. 1, Ratner and Ramaswamy Govindan, MD, have been appointed co-directors of the Section of Medical Oncology. Govindan, professor of medicine and an expert in thoracic oncology, will focus on improving clinical processes and translational science in the section. He will work closely with Ratner to enhance the link between the section’s clinical and scientific programs.
“Dr. Ratner’s research experience combined with Dr. Govindan’s clinical and translational interests will help us take the Section of Medical Oncology to new levels of excellence,” DiPersio says.
Matthew Ellis, MB, BChir, PhD, professor of medicine and Anheuser-Busch Chair in Medical Oncology, who formerly served as director of the Section of Medical Oncology, has assumed the role of director of the newly established Section of Breast Oncology.
“The section will continue efforts to make our breast cancer program one of the best in the country as measured by treatment and research advances,” DiPersio says.
The Division of Oncology also includes the clinical and translational research-focused Section of Bone Marrow Transplantation/Leukemia, headed by Peter Westervelt, MD, PhD, professor of medicine, and the research-focused Section of Stem Cell Biology, which is led by Timothy Ley, MD, Lewis T. and Rosalind B. Apple Professor of Medicine.